- IMBRUVICA ASSOCIATED WITH SIGNIFICANT IMPROVEMENTS IN KEY ENDPOINTS INCLUDING REDUCTION OF THE RISK OF DISEASE PROGRESSION OR DEATH VERSUS...
Read more• New data from Phase I/II clinical trial presented at ESMO Asia 2015 Congress showcase the potential for BI 1482694*...
Read moreClinical Trials to Evaluate Merck’s KEYTRUDA® (pembrolizumab) in Combination with Other Medicines and Treatments Across Multiple Tumor Types Merck (NYSE:MRK),...
Read moreClinical trial to assess safety and efficacy of immuno-oncology combination in patients with advanced NSCLC or melanoma Syndax Pharmaceuticals,...
Read moreMerck (NYSE:MRK), known as MSD outside the United States and Canada, and DNAtrix today announced they have entered into an...
Read more• 11 billion euro R&D programme through 2020, with 5 billion euro dedicated to pre-clinical R&D and 1.5 billion euro...
Read moreYour Time campaign calls for earlier action in COPDWHO expects COPD to be the third leading cause of death worldwide...
Read moreCollaborations aim to speed research and development approaches in Crohn’s disease and ulcerative colitisIcahn School of Medicine, Massachusetts General Hospital,...
Read morePhase III clinical trial for BI695501, a biosimilar candidate for AbbVie’s Humira®, fully enrolledRecently announced Phase I trial results show...
Read moreStudies show significant improvement with Spiolto® Respimat® in lung function across a range of age groups of patients* with COPD...
Read more
Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.
